{"id":"https://openalex.org/W4394963709","doi":"https://doi.org/10.1182/bloodadvances.2023011307","title":"Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials","display_name":"Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials","publication_year":2024,"publication_date":"2024-04-19","ids":{"openalex":"https://openalex.org/W4394963709","doi":"https://doi.org/10.1182/bloodadvances.2023011307","pmid":"https://pubmed.ncbi.nlm.nih.gov/38640349","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11255369"},"language":"en","primary_location":{"id":"doi:10.1182/bloodadvances.2023011307","doi":"https://doi.org/10.1182/bloodadvances.2023011307","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023011307","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023011307/2222674/bloodadvances.2023011307.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023011307/2222674/bloodadvances.2023011307.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0003-4529-2003","affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013007045","display_name":"Jeff Porter Sharman","orcid":"https://orcid.org/0000-0001-5611-6115","observed_orcids":["https://orcid.org/0000-0001-5611-6115"]},"institutions":[{"id":"https://openalex.org/I4210148213","display_name":"Willamette Valley Cancer Institute and Research Center","ror":"https://ror.org/05jr8e497","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210148213"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeff P. Sharman","raw_affiliation_strings":["2Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR","institution_ids":["https://openalex.org/I4210148213"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087770514","display_name":"Paolo Ghia","orcid":"https://orcid.org/0000-0003-3750-7342","observed_orcids":["https://orcid.org/0000-0003-3750-7342"]},"institutions":[{"id":"https://openalex.org/I154387261","display_name":"Vita-Salute San Raffaele University","ror":"https://ror.org/01gmqr298","country_code":"IT","type":"education","lineage":["https://openalex.org/I154387261"]},{"id":"https://openalex.org/I4210133214","display_name":"IRCCS Ospedale San Raffaele","ror":"https://ror.org/039zxt351","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210133214","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Paolo Ghia","raw_affiliation_strings":["3Division of Experimental Oncology, Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy","4Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy"],"raw_orcid":"https://orcid.org/0000-0003-3750-7342","affiliations":[{"raw_affiliation_string":"3Division of Experimental Oncology, Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy","institution_ids":["https://openalex.org/I154387261"]},{"raw_affiliation_string":"4Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy","institution_ids":["https://openalex.org/I4210133214"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014241029","display_name":"Jennifer Ann Woyach","orcid":"https://orcid.org/0000-0002-3403-9144","observed_orcids":["https://orcid.org/0000-0002-3403-9144"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer A. Woyach","raw_affiliation_strings":["5The Ohio State University Comprehensive Cancer Center, Columbus, OH","The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"],"raw_orcid":"https://orcid.org/0000-0002-3403-9144","affiliations":[{"raw_affiliation_string":"5The Ohio State University Comprehensive Cancer Center, Columbus, OH","institution_ids":["https://openalex.org/I2799885155"]},{"raw_affiliation_string":"The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","institution_ids":["https://openalex.org/I2799885155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053298824","display_name":"Toby Andrew Eyre","orcid":"https://orcid.org/0000-0002-6631-9749","observed_orcids":["https://orcid.org/0000-0002-6631-9749"]},"institutions":[{"id":"https://openalex.org/I4210147381","display_name":"Oxford University Hospitals NHS Trust","ror":"https://ror.org/03h2bh287","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Toby A. Eyre","raw_affiliation_strings":["6Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-6631-9749","affiliations":[{"raw_affiliation_string":"6Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210147381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102788725","display_name":"Wojciech J. Jurczak","orcid":"https://orcid.org/0000-0003-1879-8084","observed_orcids":["https://orcid.org/0000-0003-1879-8084"]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Wojciech Jurczak","raw_affiliation_strings":["7Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krakow, Poland"],"raw_orcid":"https://orcid.org/0000-0003-1879-8084","affiliations":[{"raw_affiliation_string":"7Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krakow, Poland","institution_ids":["https://openalex.org/I4210150880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005565037","display_name":"Tanya Siddiqi","orcid":"https://orcid.org/0000-0001-5292-8298","observed_orcids":["https://orcid.org/0000-0001-5292-8298"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tanya Siddiqi","raw_affiliation_strings":["8City of Hope Comprehensive Cancer Center, Duarte, CA","City of Hope Medical Center, Duarte, California, United States"],"raw_orcid":"https://orcid.org/0000-0001-5292-8298","affiliations":[{"raw_affiliation_string":"8City of Hope Comprehensive Cancer Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]},{"raw_affiliation_string":"City of Hope Medical Center, Duarte, California, United States","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083681267","display_name":"Paulo Miranda","orcid":"https://orcid.org/0000-0001-6853-7531","observed_orcids":["https://orcid.org/0000-0001-6853-7531"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paulo Miranda","raw_affiliation_strings":["9AstraZeneca, Gaithersburg, MD","AstraZeneca, Gaithersburg, Maryland, United States"],"raw_orcid":"https://orcid.org/0000-0001-6853-7531","affiliations":[{"raw_affiliation_string":"9AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, Gaithersburg, Maryland, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057147840","display_name":"Mina Shahkarami","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mina Shahkarami","raw_affiliation_strings":["10AstraZeneca, South San Francisco, CA","AstraZeneca, South San Francisco,, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10AstraZeneca, South San Francisco, CA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, South San Francisco,, California, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110108010","display_name":"Anna M. Butturini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna Butturini","raw_affiliation_strings":["10AstraZeneca, South San Francisco, CA","AstraZeneca, Gaithersburg, Maryland, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10AstraZeneca, South San Francisco, CA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, Gaithersburg, Maryland, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022077315","display_name":"Ugochinyere A. Emeribe","orcid":"https://orcid.org/0009-0000-8251-6163","observed_orcids":["https://orcid.org/0009-0000-8251-6163"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ugochinyere Emeribe","raw_affiliation_strings":["9AstraZeneca, Gaithersburg, MD","AstraZeneca, Gaithersburg, Maryland, United States"],"raw_orcid":"https://orcid.org/0009-0000-8251-6163","affiliations":[{"raw_affiliation_string":"9AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, Gaithersburg, Maryland, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000921376","display_name":"John C. Byrd","orcid":"https://orcid.org/0000-0001-9830-0711","observed_orcids":["https://orcid.org/0000-0001-9830-0711"]},"institutions":[{"id":"https://openalex.org/I63135867","display_name":"University of Cincinnati","ror":"https://ror.org/01e3m7079","country_code":"US","type":"education","lineage":["https://openalex.org/I63135867"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John C. Byrd","raw_affiliation_strings":["11Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH","institution_ids":["https://openalex.org/I63135867"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5063755644"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":5.0407,"has_fulltext":true,"cited_by_count":19,"citation_normalized_percentile":{"value":0.96432375,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"8","issue":"13","first_page":"3345","last_page":"3359"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":1.0},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9449999928474426},{"id":"https://openalex.org/keywords/del-17p-tp53-mutation","display_name":"del(17p)/TP53 mutation","score":0.8970000147819519},{"id":"https://openalex.org/keywords/complex-karyotype","display_name":"complex karyotype","score":1.0},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":0.8740000128746033},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.7689999938011169},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.9089999794960022},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7609999775886536},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9850000143051147},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9819999933242798},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6069999933242798}],"concepts":[{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6485209465026855},{"id":"https://openalex.org/C3017906399","wikidata":"https://www.wikidata.org/wiki/Q48973845","display_name":"Pooled analysis","level":3,"score":0.6411204934120178},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.623175323009491},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6125530004501343},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6076176762580872},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5655787587165833},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.3208123445510864},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07691651582717896},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1182/bloodadvances.2023011307","doi":"https://doi.org/10.1182/bloodadvances.2023011307","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023011307","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023011307/2222674/bloodadvances.2023011307.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11255369","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11255369","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11255369/pdf/main.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Adv","raw_type":"Text"},{"id":"pmid:38640349","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38640349","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood advances","raw_type":"Journal Article"},{"id":"pmh:oai:iris.unisr.it:20.500.11768/159996","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/20.500.11768/159996","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/8/13/3345/2233973/blooda_adv-2023-011307-main.pdf","source":{"id":"https://openalex.org/S7407055348","display_name":"Archivio Istituzionale della Ricerca - Universit\u00e0 Vita-Salute San Raffaele","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1182/bloodadvances.2023011307","doi":"https://doi.org/10.1182/bloodadvances.2023011307","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023011307","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023011307/2222674/bloodadvances.2023011307.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[{"id":"https://openalex.org/G9000873194","display_name":"Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia","funder_award_id":"R01CA266298","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320309374","display_name":"Ohio State University","ror":"https://ror.org/00rs6vg23"},{"id":"https://openalex.org/F4320313971","display_name":"TG Therapeutics","ror":"https://ror.org/00pwykz63"},{"id":"https://openalex.org/F4320315663","display_name":"Sunesis","ror":"https://ror.org/0187pm092"},{"id":"https://openalex.org/F4320316491","display_name":"MEI Pharma","ror":"https://ror.org/02bgfrc80"},{"id":"https://openalex.org/F4320316872","display_name":"Adaptive Biotechnologies","ror":"https://ror.org/01gbt6a54"},{"id":"https://openalex.org/F4320317235","display_name":"BeiGene","ror":"https://ror.org/012v2c923"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320317987","display_name":"Syndax Pharmaceuticals","ror":"https://ror.org/02w9kv048"},{"id":"https://openalex.org/F4320319131","display_name":"Ascentage Pharma","ror":"https://ror.org/053nqfd77"},{"id":"https://openalex.org/F4320328062","display_name":"MorphoSys","ror":"https://ror.org/00ew7rg06"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"},{"id":"https://openalex.org/F4320333670","display_name":"Juno Therapeutics","ror":"https://ror.org/02dq5dx40"},{"id":"https://openalex.org/F4320334037","display_name":"Loxo Oncology","ror":"https://ror.org/03abe5304"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4394963709.pdf","grobid_xml":"https://content.openalex.org/works/W4394963709.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1960354891","https://openalex.org/W2142099365","https://openalex.org/W2162445884","https://openalex.org/W2500653807","https://openalex.org/W2790385276","https://openalex.org/W2948436219","https://openalex.org/W2998606818","https://openalex.org/W2999980976","https://openalex.org/W3002788758","https://openalex.org/W3016538158","https://openalex.org/W3029637120","https://openalex.org/W3088078660","https://openalex.org/W3151974300","https://openalex.org/W3185756680","https://openalex.org/W3213933946","https://openalex.org/W4200435825","https://openalex.org/W4205825534","https://openalex.org/W4213170825","https://openalex.org/W4281385697","https://openalex.org/W4284883545","https://openalex.org/W4307773195","https://openalex.org/W4308963956","https://openalex.org/W4311293040","https://openalex.org/W4366280595","https://openalex.org/W4380079293","https://openalex.org/W4385658125"],"related_works":["https://openalex.org/W4283324920","https://openalex.org/W4405046617","https://openalex.org/W2907984502","https://openalex.org/W4410238534","https://openalex.org/W4409255592","https://openalex.org/W3032542865","https://openalex.org/W4310159103","https://openalex.org/W2951808700","https://openalex.org/W2989438424","https://openalex.org/W3197706552"],"abstract_inverted_index":{"ABSTRACT:":[0],"Before":[1],"targeted":[2],"therapies,":[3],"patients":[4,86,101,130,232],"with":[5,33,47,77,87,211,233],"higher-risk":[6,44,88,234],"chronic":[7],"lymphocytic":[8],"leukemia":[9],"(CLL),":[10],"defined":[11],"as":[12,72],"del(17p)":[13],"and/or":[14],"TP53":[15],"mutation":[16],"(TP53m),":[17],"unmutated":[18],"immunoglobulin":[19],"heavy":[20],"chain":[21],"variable":[22],"region":[23],"genes":[24],"(uIGHV),":[25],"or":[26,74,93],"complex":[27],"karyotype":[28],"(CK),":[29],"had":[30],"poorer":[31],"prognosis":[32],"chemoimmunotherapy.":[34],"Bruton":[35],"tyrosine":[36],"kinase":[37],"inhibitors":[38],"(BTKis)":[39],"have":[40],"demonstrated":[41],"benefit":[42,227],"in":[43,49,75,85,90,131,151,175,206,218,231],"patient":[45],"populations":[46],"CLL":[48,89,221],"individual":[50],"trials.":[51],"To":[52],"better":[53],"understand":[54],"the":[55,58,132,145,152,169,176,212],"impact":[56],"of":[57,70,99,129,203,216,228,237,239],"second-generation":[59],"BTKi":[60],"acalabrutinib,":[61],"we":[62],"pooled":[63],"data":[64],"from":[65],"5":[66],"prospective":[67],"clinical":[68],"studies":[69],"acalabrutinib":[71,217],"monotherapy":[73],"combination":[76],"obinutuzumab":[78],"(ACE-CL-001,":[79],"ACE-CL-003,":[80],"ELEVATE-TN,":[81],"ELEVATE-RR,":[82],"and":[83,121,127,134,148,159,172,186,190,197],"ASCEND)":[84],"treatment-naive":[91],"(TN)":[92],"relapsed/refractory":[94],"(R/R)":[95],"cohorts.":[96],"A":[97],"total":[98],"808":[100],"were":[102,164],"included":[103],"(TN":[104,119],"cohort,":[105,110,154,178],"n":[106,111],"=":[107,112],"320;":[108],"R/R":[109,135,177],"488).":[113],"Median":[114],"follow-up":[115],"was":[116,181,193,209],"59.1":[117],"months":[118,123],"cohort)":[120],"44.3":[122],"(R/R":[124],"cohort);":[125],"51.3%":[126],"26.8%":[128],"TN":[133,153],"cohorts,":[136],"respectively,":[137,189],"remained":[138],"on":[139],"treatment":[140],"at":[141],"last":[142],"follow-up.":[143],"In":[144,168],"del(17p)/TP53m,":[146,170],"uIGHV,":[147,171],"CK":[149,173],"subgroups":[150,174],"median":[155,160,179,191],"progression-free":[156],"survival":[157,162],"(PFS)":[158],"overall":[161],"(OS)":[163],"not":[165],"reached":[166],"(NR).":[167],"PFS":[180],"38.6":[182,187],"months,":[183,185,188,195],"46.9":[184],"OS":[192],"60.6":[194],"NR,":[196,198],"respectively.":[199],"The":[200],"safety":[201,214],"profile":[202,215],"acalabrutinib-based":[204,229],"therapy":[205],"this":[207],"population":[208],"consistent":[210],"known":[213],"a":[219],"broad":[220],"population.":[222],"Our":[223],"analysis":[224],"demonstrates":[225],"long-term":[226],"regimens":[230],"CLL,":[235],"regardless":[236],"line":[238],"therapy.":[240]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-04-20T00:00:00"}